Amphiphysin autoimmunity: Paraneoplastic accompaniments
Sean J. Pittock MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Departments of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorClaudia F. Lucchinetti MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorJoseph E. Parisi MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Departments of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorEduardo E. Benarroch MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorBahram Mokri MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorChristina L. Stephan MD
Departments of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorKwang-Kuk Kim MD, PhD
Department of Neurology, University of Visan College of Medicine, Seoul, Korea
Search for more papers by this authorManfred W. Kilimann MD
Department of Cell and Molecular Biology, Uppsala University Biomedical Center, Uppsala, Sweden
Search for more papers by this authorCorresponding Author
Vanda A. Lennon MD, PhD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Departments of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN
Neuroimmunology Laboratory, Guggenheim Building, Rm. 828, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905Search for more papers by this authorSean J. Pittock MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Departments of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorClaudia F. Lucchinetti MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorJoseph E. Parisi MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Departments of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorEduardo E. Benarroch MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorBahram Mokri MD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorChristina L. Stephan MD
Departments of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Search for more papers by this authorKwang-Kuk Kim MD, PhD
Department of Neurology, University of Visan College of Medicine, Seoul, Korea
Search for more papers by this authorManfred W. Kilimann MD
Department of Cell and Molecular Biology, Uppsala University Biomedical Center, Uppsala, Sweden
Search for more papers by this authorCorresponding Author
Vanda A. Lennon MD, PhD
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN
Departments of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN
Neuroimmunology Laboratory, Guggenheim Building, Rm. 828, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905Search for more papers by this authorAbstract
Amphiphysin-IgG was identified in 71 patients among 120,000 evaluated serologically for paraneoplastic autoantibodies. Clinical information was available for 63 patients. Cancer was detected in 50 (mostly limited), proven histologically in 46, and was imaged intrathoracically in 4 patients (lung, small–cell [27] and non–small cell [1]), breast [16] and melanoma [2]). Neurological accompaniments included (decreasing frequency): neuropathy, encephalopathy, myelopathy, stiff-man phenomena, and cerebellar syndrome. In a case examined neuropathologically, parenchymal T-lymphocyte infiltration (predominantly CD8+) was prominent in lower brainstem, spinal cord, and dorsal root ganglion. Coexisting paraneoplastic autoantibodies, identified in 74% of patients, predicted a common neoplasm and indicated other neuronal autoantigen targets that plausibly explained several neurological manifestations; for example, P/Q-type Ca2+-channel antibody with Lambert–Eaton syndrome (n = 5), anti-neuronal nuclear antibody type 1 with sensory neuronopathy (n = 7), K+-channel antibody with limbic encephalitis (n = 1) or neuromyotonia (n = 1), and collapsin response-mediator protein-5-IgG with optic neuritis (n = 3). Patients with isolated amphiphysin-IgG (n = 19) were more likely to be women (with breast cancer, p < 0.05) and to have myelopathy or stiff-man phenomena (p < 0.01). Overall, a minority of women (39%) and men (12%) had stiff-man phenomena. Only 10% of women (some with lung carcinoma) and 4% of men fulfilled diagnostic criteria for stiff-man syndrome. Ann Neurol 2005;58:96–107
References
- 1 Lichte B, Veh RW, Meyer HE, Kilimann MW. Amphiphysin, a novel protein associated with synaptic vesicles. EMBO J 1992; 11: 2521–2530.
- 2 De Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 1993; 178: 2219–2223.
- 3 Moersch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome): report of a case and some observations in 13 other cases. Mayo Clin Proc 1956; 31: 421–427.
- 4 Folli F, Solimena M, Cofiell R, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328: 546–551.
- 5 Dropcho EJ. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996; 39: 659–667.
- 6 Antoine JC, Absi L, Honnorat J, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999; 56: 172–177.
- 7 Lennon VA, Manley HA, Kim KK, et al. Amphiphysin autoantibodies: a paraneoplastic serological marker of breast and lung cancer-related encephalomyeloradiculoneuritides but not classical stiffman syndrome. Neurology 1997; 48( suppl 2): A434.
- 8 Saiz A, Dalmau J, Butler MH, et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 1999; 66: 214–217.
- 9 Lennon VA, Ermilov LG, Szurszewski JH, Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003; 111: 907–913.
- 10 Vernino S, Ermilov LG, Sha L, et al. Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci 2004; 24: 7037–7042.
- 11 Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25: 313–319.
- 12 Tanaka K, Tanaka M, Inuzuka T, et al. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J Neurol Sci 1999; 163: 159–166.
- 13 Tanaka M, Tanaka K, Shinozawa K, et al. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1998; 161: 88–90.
- 14 Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4: 1321–1324.
- 15 Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001; 50: 301–311.
- 16 Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49: 146–154.
- 17 Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53: 580–587.
- 18 Vernino S, Kryzer TJ, Lennon VA. Autoimmune autonomic neuropathy and neuromuscular hyperexcitability disorders. In: NR Rose, E Conway De Macario, D Folds, et al, eds. Manual of clinical and laboratory immunology. 6th ed. Washington, DC: ASM Press, 2002: 1013–1017.
- 19 Walikonis JE, Lennon VA. Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc 1998; 73: 1161–1166.
- 20 Vass K, Lassmann H, Wekerle H, Wisniewski HM. The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis. Acta Neuropathologica 1986; 70: 149–160.
- 21 Vass K, Welch WJ, Nowak TS Jr. Localization of 70-kDa stress protein induction in gerbil brain after ischemia. Acta Neuropathologica 1988; 77: 128–135.
- 22 Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54: 38–50.
- 23 Yamamoto R, Li X, Winter S, et al. Primary structure of human amphiphysin, the dominant autoantigen of paraneoplastic stiff-man syndrome, and mapping of its gene (AMPH) to chromosome 7p13–p14. Hum Mol Genet 1995; 4: 265–268.
- 24 Schmierer K, Grosse P, De Camilli P, et al. Paraneoplastic stiff-person syndrome: no tumor progression over 5 years. Neurology 2002; 58: 148.
- 25 Rosin L, DeCamilli P, Butler M, et al. Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. Neurology 1998; 50: 94–98.
- 26 Lorish TR, Thorsteinsson G, Howard FM Jr. Stiff-man syndrome updated. Mayo Clin Proc 1989; 64: 629–636.
- 27 Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic autoantibodies commonly coexist and predict cancer not neurologic syndrome. Ann Neurol 2004; 56: 715–719.
- 28 Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002; 51: 625–630.
- 29 Lee HR, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 2001; 96: 373–379.
- 30 Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine 1992; 71: 59–72.
- 31 Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncological profiles of patients seropositive for type 1 anti-neuronal nuclear autoantibodies. Neurology 1998; 50: 652–657.
- 32 Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001; 50: 73–78.
- 33 Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve 2002; 26: 702–707.
- 34 Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332: 1467–1474.
- 35 Griesmann GE, Kryzer TJ, Lennon VA. Autoantibody profiles of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: NR Rose, E Conway De Macario, D Folds, et al, eds. Manual of clinical and laboratory immunology. 6th ed. Washington, DC: ASM Press, 2002: 1005–1012.
- 36 Wessig C, Klein R, Schneider MF, et al. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003; 61: 195–198.
- 37 Pittock SJ, Parisi JE, Keegan M, et al. Jaw opening dystonia and laryngospasm associated with paraneoplastic ANNA-2 autoantibody. Ann Neurol 2003; 54( suppl 7): S70.